The observation that these two LSC populations coexist in 80% of patients9 and that the primitive LMPP-like LSCs are found enriched in recurrent AML55 warrants clinical investigation of CD37 CAR T cells in AML treatment. The gene discussed is CD37; the disease is acute myeloid leukemia.